Table II.
Adverse events per dose cohort at cycle 1.
| Erlotinib dose | MO17974 trial (n=12)
|
ML18511 trial (n=9)
|
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 100 mg (n=3) | 125 mg (n=3) | 150 mg (n=6) | 100 mg (n=3) | 125 mg (n=3) | 150 mg (n=6) | 100 mg (n=6) | 150 mg (n=3) | 100 mg (n=6) | 150 mg (n=3) | |
|
|
|
|
|
|||||||
| Grade 1–2 | Grade 3–4 | Grade 1–2 | Grade 3–4 | |||||||
| Mucositis | 1 | - | - | - | - | - | ||||
| Diarrhea | 1 | - | 1 | - | - | 1 | 4 | 1 | - | 1 |
| Asthenia | - | 1 | - | - | - | - | ||||
| Nausea | 1 | 1 | 3 | - | - | - | ||||
| Vomiting | 1 | 1 | - | - | ||||||
| Anemia | - | - | 1 | - | - | - | 1 | 1 | - | - |
| Neutropenia | - | - | 1 | - | - | 1 | ||||
| Constipation | - | - | 1 | - | - | - | ||||
| Neurotoxicity | - | - | 1 | - | - | - | - | 2 | - | - |
| Skin rash | - | - | 1 | - | - | - | 3 | 1 | - | - |
| Rectal bleeding | - | 1 | - | - | ||||||
| Proctitis | 1 | - | - | - | ||||||